| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.8 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.095 | 0.8 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.0094 | 0.8 |